Resultats globals: 2 registres trobats en 0.02 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
7 p, 199.8 KB CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer / Chiorean, E. G. (University of Washington. Department of Medicine) ; Von Hoff, D. D. (Translational Genomics Research Institute) ; Reni, M. (Ospedale San Raffaele. Servizio di Oncologia Medica) ; Arena, F. P. (NYU Langone Arena Oncology. Department of Oncology) ; Infante, J. R. (Sarah Cannon Research Institute) ; Bathini, V. G. (University of Massachusetts Medical School. Cancer Center of Excellence) ; Wood, T. E. (University of Alabama at Birmingham. Comprehensive Cancer Center) ; Mainwaring, P. N. (Centre for Haematology & Oncology (Brisbane, Austràlia)) ; Muldoon, R. T. (Genesis Cancer Center. Department of Oncology) ; Clingan, P. R. (Southern Medical Day Care Centre) ; Kunzmann, V. (Universitätsklinikum Würzburg. Medizinischen Klinik und Poliklinik II) ; Ramanathan, R. K. (Translational Genomics Research Institute) ; Tabernero Caturla, Josep (Hospital Universitari de la Vall d'Hebron) ; Goldstein, D. (Prince of Wales Hospital. Department of Oncology) ; McGovern, D. (Celgene Corporation) ; Lu, B. (Celgene Corporation) ; Ko, A. (Celgene Corporation) ; Universitat Autònoma de Barcelona
Any CA19-9 decline at week 8 and radiologic response by week 8 each predicted longer OS in both treatment arms. In the nab- P + Gem arm, the higher proportion of patients with week 8 CA19-9 decrease [82% (206/252); median OS 13. [...]
2016 - 10.1093/annonc/mdw006
Annals of oncology, Vol. 27, issue 4 (April 2016) , p. 654-660  
6 p, 180.0 KB Positron emission tomography response evaluation from a randomized phase III trial of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas / Ramanathan, R. K. (Mayo Clinic (USA)) ; Goldstein, D. (Prince of Wales Hospital (Australia)) ; Korn, R. L. (Scottsdale Medical Imaging, Ltd (USA)) ; Arena, F. (NYU Langone Arena Oncology (USA)) ; Moore, M. (Provencial Health Services Authority. BC Cancer Agency (Canada)) ; Siena, S. (Università degli Studi di Millano. Niguarda Cancer Center (Italy)) ; Teixeira, L. (Hôpital Saint-Antoine (France)) ; Tabernero Caturla, Josep (Institut d'Oncologia de la Vall Hebron (VHIO)) ; Van Laethem, J.-L. (University Clinic of Brussels. Hôpital Erasme (Belgium)) ; Liu, H. (Biostatistics and Research and Design. Celgene Corporation (USA)) ; McGovern, D. (Biostatistics and Research and Design. Celgene Corporation (USA)) ; Lu, B. (Biostatistics and Research and Design. Celgene Corporation (USA)) ; Von Hoff, D. D. (Translational Genomics Research Institute and Honor Health (USA)) ; Universitat Autònoma de Barcelona
In a phase III pancreatic cancer study, tumor response by positron emission tomography (PET) (exploratory end point) predicted treatment efficacy, including longer overall survival. nab -Paclitaxel/gemcitabine had a significantly higher rate of metabolic response versus gemcitabine. [...]
2016 - 10.1093/annonc/mdw020
Annals of Oncology, Vol. 27, Issue 4 (April 2016) , p. 648-653  

Vegeu també: autors amb noms similars
2 Ramanathan, R. K.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.